Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study of GST-HG131&141 Tablets Compared With Placebo in Patients With Chronic Hepatitis B
Sponsor: Fujian Akeylink Biotechnology Co., Ltd.
Summary
A randomized, double-blind, placebo-controlled Phase IIa clinical study to evaluate the safety and efficacy of GST-HG131/GST-HG141 tablets in patients with chronic hepatitis B
Official title: A Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Safety and Efficacy of GST-HG131/ GST-HG141 Tablets in Patients With Chronic Hepatitis B
Key Details
Gender
All
Age Range
35 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
80
Start Date
2026-07-10
Completion Date
2026-12-01
Last Updated
2026-07-16
Healthy Volunteers
No
Conditions
Interventions
GST-HG141
GST-HG141 is a novel, potent and selective HBV CAM, which has a distinct molecular mechanism of its antiviral action compared to other CAMs reported in the literature, and has demonstrated strong antiviral properties in pre-clinical studies in vitro and in vivo.
GST-HG131
GST-HG131 is a novel dihydroquinolizinone (DHQ) compound, has been shown to reduce circulating levels of HBsAg in animals.
GST-HG141 Placebo
GST-HG141 Placebo
Locations (1)
Beijing Friendship Hospital, Capital Medical University
Beijing, China